| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_408a673e5f3674e77d63dfe2a7856215 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7024
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-665
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-662 |
| filingDate |
2010-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fad061c649eefaf9c6f48a492e2c0aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0446f430f817b71b7be522b505fdd278
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cacac742723cce6bfce7ae32d198a26d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb74b4e1757ee649c9525ccd6acc197c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bab08a7b57e9712baa72b92408e144b9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d0bf15ccf5b222a01fac079e4350a13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b5036b178453118f9713cfa68457b62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef172eee1a4abfdf5f386ed1888c5fa9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bac099d4198f74bf722fc33b47b42c04 |
| publicationDate |
2011-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-201114429-A |
| titleOfInvention |
Inhibition of tendon adhesions |
| abstract |
The invention provides composition having an osmolality of at least 1200 mOsmol for use as a medicament for the inhibition of tendon adhesion formation. The compositions of the invention may comprises a sugar phosphate, such as mannose-6-phosphate (M6P) and/or glucose-6-phosphate (G6P). Composition comprising M6P are particularly favoured. The compositions may improve tendon repair by increasing the quality of replacement tendon formed after injury, and may be well suited to administration by injection. |
| priorityDate |
2009-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |